Holen Sie sich die Stockscreener-App
10.31
5.96%
0.58
Vorhandelsmarkt:
10.49
0.18
+1.75%
Schlusskurs vom Vortag:
$9.73
Offen:
$9.79
24-Stunden-Volumen:
1.89M
Relative Volume:
0.87
Marktkapitalisierung:
$887.15M
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-3.4831
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
+11.94%
1M Leistung:
+8.76%
6M Leistung:
-26.36%
1J Leistung:
-55.92%
1-Tages-Spanne:
$9.68
$10.37
1-Wochen-Bereich:
$9.03
$10.37
52-Wochen-Spanne:
$8.58
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
10.31 | 792.50M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 Shares - MarketBeat
Syndax Pharmaceuticals Inc. Stock Analysis and ForecastMarket-crushing profits - jammulinksnews.com
Is Syndax Pharmaceuticals Inc. a good long term investmentFree Capital Efficiency Planning - jammulinksnews.com
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Acquires New Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What drives Syndax Pharmaceuticals Inc. stock priceFree Smart Trading Workshop - jammulinksnews.com
What analysts say about Syndax Pharmaceuticals Inc. stockRemarkably fast returns - jammulinksnews.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Michael A. Metzger Sells 7,534 Shares - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Teacher Retirement System of Texas - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $34.10 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group - MarketBeat
Top Executives at Syndax Pharmaceuticals Make Significant Stock Moves! - TipRanks
Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Is Syndax Pharmaceuticals Inc. stock a good hedge against inflationFree Insider Trading Tips - Newser
Will Syndax Pharmaceuticals Inc. stock benefit from interest rate changesBreakout Confirmation Tool - Newser
(SNDX) Trading Advice - news.stocktradersdaily.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% Following Analyst Downgrade - MarketBeat
UBS Group Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% on Analyst Downgrade - Defense World
Syndax CFO and CEO sell shares at $9.29/share on July 16, 2025. - AInvest
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML - MSN
Why Syndax Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - Newser
What makes Syndax Pharmaceuticals Inc. stock price move sharplyPro Trader Stock Focus - Newser
UBS Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $35 - GuruFocus
How Syndax Pharmaceuticals Inc. stock performs during market volatilityFree Day Trading Recommendations - Newser
UBS Adjusts Price Target on Syndax Pharmaceuticals Inc to $35 From $37, Maintains Buy Rating - MarketScreener
UBS Adjusts Price Target for Syndax (SNDX) While Maintaining Pos - GuruFocus
The Goldman Sachs Group Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 6.7% HigherShould You Buy? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at The Goldman Sachs Group - Defense World
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):